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Abstract
Background: Cervical dystonia (CD) is a debilitating neurological disorder that may gravely affect a patient’s quality of life (QoL). Botulinum toxin treatment has
been approved as a first-line treatment for this condition. This study aims to look at the efficacy and impact on the QoL of neu-botulinumtoxinA, a newer and
cheaper botulinum toxin type A, in patients with CD.
Methods: This is a prospective, open-label, single-arm study. CD patients were recruited and evaluated for severity of CD using the Toronto Western Spasmodic
Torticollis Rating Scale (TWSTRS), and for QoL using the Craniocervical Dystonia Questionnaire (CDQ-24), and the 36-item Short Form Health Survey
questionnaire (SF-36) at baseline and 6 weeks after injection.
Results: Twenty patients were recruited. Significant improvement was shown in part 1 and total TWSTRS score and total CDQ-24 scores. Analysis of individual
items of the TWSTRS scale showed significant improvement in rotation, duration of CD, and work ability. Significant improvements in the QoL were also seen in
some items of the stigma, emotional wellbeing, and energy/fatigue domains of the CDQ-24 and SF-36 questionnaires.
Discussion: Neu-botulinumtoxinA is efficacious in treating CD symptoms and improving QoL of patients with CD. A larger, double-blinded study is needed to
study the extent of improvements.
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Introduction
Cervical dystonia (CD) is a neurological condition in which
excessive involuntary muscle contraction causes abnormal posture
and movement of the head and neck.1,2 It may be accompanied by
pain and head tremor. These can cause disability, a negative self-
image, and decreased quality of life (QoL).3–6 Apart from these, other
factors, such as depression, ability to cope with the disease, severity and
duration of dystonia, female gender, stigma, and poor financial
situation, also play significant roles in determining the QoL of CD
patients.4,7–10 The negative impact of CD can be significant and is
similar to Parkinson’s disease, multiple sclerosis, and stroke.5,11
Botulinum toxin (BTX) injection, especially BTX type A (BTX-A),
has been accepted as the treatment of choice for patients with CD.
Neu-botulinumtoxinA (N-BTX, NeuronoxH) is a relatively new BTX-A
that has been approved for various therapeutic and cosmetic indications
in some Asian and Latin American countries. It is produced by the Hall A
strain of Clostridium botulinum and purified to produce a homogeneous
900-kD toxin complex. It has been shown to be non-inferior to
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onabotulinumtoxinA (Ona-BTX, BotoxH) in the treatment of blephar-
ospam, moderate to severe glabellar lines, post-stroke upper limb
spasticity, and spastic equinus gait in children with cerebral palsy.12–16
Its cost is lower than Ona-BTX and abobotulinumtoxinA (Abo-BTX,
DysportH) by approximately 10–30%.
The purpose of this study was to investigate the efficacy and impact
on the QoL of N-BTX treatment in CD patients.
Methods
This was a prospective, open label, single-arm study. The primary
objective of the study was to study the efficacy of N-BTX on the
severity of CD. The secondary objective was to study its impact on the
QoL of patients with CD. The study was approved by the Institutional
Review Board of the Faculty of Medicine, Chulalongkorn University.
Patients with CD were recruited from the BTX clinic of Chulalongkorn
Center of Excellence for Parkinson’s Disease and Related Disorders.
Patients with CD who were >18–75 years old were eligible to
participate in the study. Patients were excluded if they were in any of
these categories: patients who had been treated with BTX-A within
3 months; females who were pregnant, planning pregnancy, unable to
use contraception, or lactating; and any medical condition that may
have put the subject at increased risk with exposure to BTX at the
discrimination of investigators.
If patients were taking concomitant oral medications for dystonia,
the medicines and doses were left unchanged during the study period.
Patients were evaluated using the Toronto Western Spasmodic
Torticollis Rating Scale (TWSTRS), a specific scale to rate cervical
dystonia divided into severity, disability, and pain subscales; the
Craniocervical Dystonia Questionnaire (CDQ-24), a disease-specific
questionnaire to evaluate QoL of patients with CD and blepharospasm
based on five subscales: stigma, emotional wellbeing, pain, activities of
daily living (ADL), and social/family life17; and the 36-item Short
Form Health Survey questionnaire (SF-36), which is a generic measure
of QoL18,19 looking at eight domains: physical functioning, role
limitations due to physical health, role limitations due to emotional
problems, energy/fatigue, emotional wellbeing, social functioning,
pain, and general health. These scales were administered at baseline
and 6 weeks after injection. At 6 weeks, the subject’s overall satisfaction
was also evaluated by asking how satisfied they were with the
treatment (very unsatisfied, unsatisfied, slightly unsatisfied, not so bad,
slightly satisfied, satisfied, and very satisfied).
Patients were evaluated by TWSTRS and injected according to the
type of CD by movement disorders neurologists. The doses were based
on prior BTX treatment with other types of toxins and adjusted
according to the patient’s current symptoms. The dose conversion
ratio for Ona-BTX was 1:1 and for Abo-BTX was 1:2–3.12,14,20 The
CDQ-24, SF-36 questionnaires, and the subject’s overall satisfaction
scale were self-administered by the patients or the questions were asked
by a movement disorders nurse when the patients had difficulty
reading or were uneducated and the answers were provided by the
patients.
Statistics
For demographics, disease characteristics, and the subject’s overall
satisfaction, descriptive statistics were used. Outcome variables were
evaluated using the Wilcoxon Signed Rank Test. A p-value #0.05 was
considered statistically significant.
Results
A total of 20 patients were enrolled in the study. Baseline demo-
graphics and disease characteristics are shown in Table 1. Two of the
20 patients had secondary CD, one from cerebral palsy and the other
from iron accumulation in the basal ganglia from an unidentified
cause. Their diseases were non-progressive or very slowly progressive
over the past 5 years of follow-up. The mean last dose of Ona-BTX
before entering the study was 81.04 units (range 0–262 units, SD¡ 77.3)
and of Abo-BTX was 394 units (range 210–500 units, SD¡ 129.6). All
the patients had at least one concomitant oral medication for dystonia.
These included anticholinergics, baclofen, clonazepam, levodopa,
sirdalud, gabapentin, and pregabalin. The doses were left unchanged
during the study period.
The mean dose of N-BTX injected was 120 units (range 30–300 units,
SD ¡ 69). Part 1 (severity) and the total TWSTRS scores improved
significantly post-injection (p50.006 and 0.010 respectively). Analysis of
individual points of the TWSTRS scale revealed significant changes
in rotation (p 5 0.008), duration factor (p 5 0.003), and work ability
(p 5 0.047) (part 2) scores. The results of other outcomes are shown
in Table 2.
Analysis of each of the domains of SF-36 and CDQ-24 did not show
significant difference before and after the treatment. However, the
total CDQ-24 score was significantly different (p 5 0.05). Detailed
analysis of the CDQ-24 and SF-36 questionnaires revealed that
questions 12 and 22 of the CDQ-24, ‘‘have you felt afraid’’ (emotional
wellbeing) and ‘‘have you felt you didn’t look so good’’ (stigma),
respectively, and questions 23 and 31 of the SF-36 questionnaire, ‘‘did
you feel full of pep’’ and ‘‘did you feel tired’’, respectively, both of
which are in the energy/fatigue domain, were statistically significantly
different at baseline and 6 weeks after injection (p-values of 0.035,
0.022, 0.036 and 0.033, respectively).
At 6 weeks, most patients were either satisfied (40%) or slightly
satisfied (35%) with the result of the injection (Figure 1).
There was no major adverse event from the injection. One patient
complained of headache after injection that was resolved by
acetaminophen. The others did not complain of any adverse events.
Discussion
This is the first study of N-BTX in CD patients. It shows that
N-BTX is efficacious in treating symptoms of CD shown by significant
changes in part 1 and total TWSTRS scores. The efficacy was more
prominent in rotation and duration of CD reduction and increase in
work ability. The total score of CDQ-24, a QoL questionnaire
specifically designed for CD patients, significantly improved after
N-BTX injection. The total SF-36 score was not significantly different,
but some parts of both the SF-36 and the CDQ-24 questionnaires
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Table 1. Baseline Demographics and Disease Characteristics
Demographic Variables Study Population (n 5 20)
Gender: male, n (%) 11 (55)
Mean (range) age, years 45.8 (24–73)
Mean (range) age at onset, years 38.8 (7–67)
Mean (range) estimated duration of cervical dystonia, years 7.0 (1–19)
Pain at onset, n (%) 9 (45.0)
Tremor at onset, n (%) 11 (55.0)
Jerk at onset, n (%) 3 (15.0)
Sensory tricks at onset, n (%) 5 (25.0)







Torticollis + laterocollis 6 (30)
Torticollis + retrocollis 1 (5)
Torticollis + anterocollis 1 (5)
Torticollis + laterocollis + retrocollis 1 (5)
Torticollis + laterocollis + anterocollis 3 (15)
Number of injections before entering the study
Never, n (%) 1 (5)
1–5, n (%) 10 (50)
6–10, n (%) 1 (5)
11–15, n (%) 4 (20)
16–25, n (%) 4 (20)
Duration of injection before entering the study (years)
Never, n (%) 1 (5)
1–5, n (%) 13 (65)
6–10, n (%) 5 (25)
11–15, n (%) 1 (5)
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in stigma, emotional wellbeing, and energy/fatigue domains show
statistically significant improvement. This may imply that when the
motor symptoms of CD improve, some aspects of energy level and
self-perception are more sensitive to change than other aspects and
domains, and that these changes can be brought about by BTX
treatment. Most of the patients were satisfied with the outcome of the
treatment. This is in line with the study by Sethi et al.21 that looked
into CD patients’ satisfaction with BTX treatment that revealed that
most patients were satisfied with their treatment and about 6.6% were
unsatisfied.
Previous studies looking at the QoL of CD patients have shown that
BTX-A treatment improves the patients’ QoL and TWSTRS or Tsui
scores, as early as 4 weeks after the first injection, and this increases
with the duration of treatment.5–7,9,17,22 In the largest, prospective,
open-label study of 516 CD patients by Hefter et al.,6 there were
significant changes in the total and subscale scores of the CDQ-24 pain
and day-to-day capacity at week 4 that was sustained at week 12 after
Abo-BTX treatment. Another study by Skogseid et al.9 looking at the
QoL of 70 CD patients (median duration of BTX treatment 5.5 years)
concluded that most CD patients enjoy a good QoL after long-term
BTX-A therapy. Slawek et al.7 studied the impact of BTX-A on the
QoL in 101 CD patients, and improvement was seen in all the SF-36
domains. Smaller studies, however, have shown improvement in only
some domains. Mordin et al.5 analyzed the effect of Abo-BTX on QoL
in 45 CD patients compared with 38 controls. The SF-36 improved
in certain domains: physical functioning, role limitations because
of physical health, bodily pain, general health, and role limitations
because of emotional problems. Another smaller study by Hilker
et al.22 (25 CD patients) showed improvement in energy and vitality,
social functioning, mental health (emotional wellbeing), limitations
because of physical problems, and pain domains of the SF-36. This
may explain why there were no significant differences in individual
domains of the two QoL questionnaires in this study. The effect
seems to be more prominently evident with the increased number of
patients recruited in the studies. As this was a small study, the effect
may not have been revealed.
Another explanation for the lack of statistically significant improve-
ment in the QoL and other symptoms of patients in the study may be
due to patient profiles. Most of the patients that entered the study did
not have much disability, pain, and poor QoL specifically caused by CD,
Table 2. Outcome Variables
Outcome Measure
Mean score (n 5 20)
p
Baseline 6 Weeks after Injection
TWSTRS
Part 1: severity (max 5 35)1 19.55 16.5 0.006
Part 2: disability (max 5 30)1 6.5 5.1 0.210
Part 3: pain (max 5 20)1 6.65 5.64 0.322
Total score (max 5 85)1 26.05 21.60 0.010
CDQ-24 (max 5 100)1 29.85 25.53 0.050
SF-36 (max 5 100)1,2 56.26 59.63 0.709
Abbreviations: CDQ-24, Craniocervical Dystonia Questionnaire; SF-36, Craniocervical Dystonia Questionnaire; TWSTRS, Toronto Western Spasmodic Torticollis
Rating Scale.
1Maximum possible score.
2Higher SF-36 score indicates better health.
Table 1. Continued
Demographic Variables Study Population (n 5 20)
Previous Ona-BTX injection, n (%) 14 (70)
Previous Abo-BTX injection, n (%) 6 (30)
Previous Ona-BTX and Abo-BTX injection, n (%) 2 (10)
Abbreviations: Abo-BTX, AbobotulinumtoxinA; Ona-BTX, OnabotulinumtoxinA.
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as the baseline scores of part 2 and 3 of TWSTRS and total CDQ-24
were not high. Moreover, the patients were quite diversified, as shown
by wide standard deviation (SD) of the mean baseline total TWSTRS
score (SD 5 10.185) and mean baseline total CDQ-24 score (SD 5
20.671). These may be the reasons for the above scores not being
significantly different after treatment.
There are some limitations of this study. Firstly, this was an open-
label study and the number of patients recruited was small. Patients
were quite diversified. Most of them did not have much pain and
disease-specific poor QoL. Depression was not assessed in the study
and, as mentioned above, it is one of the major predictors of the QoL
of patients with CD.7,8 Additionally, the doses of N-BTX used in the
study were quite low as they were converted from the previous BTX
doses that the patients had been injected with. The dosage of BTX was
limited by the reimbursement scheme in the country of the study. For
CD, patients can be reimbursed for not more than 300 units of Ona-
BTX per year and not more than 500 units of Abo-BTX per year.
Those who are willing to pay by themselves usually get higher doses.
Therefore, the toxin is injected into the most troublesome muscles with
the limitation of the dose in mind. A larger and a double-blind study
that includes patients with more disability, pain, and a poorer QoL
would be needed to prove the efficacy of N-BTX at improving the
non-motor symptoms and the QoL of patients with CD. Using the
outcome of this study, the sample size that would be required would be
at least 89.
In conclusion, N-BTX is a cheaper alternative and is efficacious in
treating the symptoms of CD and helps improve a patient’s QoL.
A larger, double-blind study is needed to confirm the result.
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